CagriSema is an investigational combination therapy, pairing cagrilintide with semaglutide, and is discussed here in comparison to other incretin-based treatments. This page compares CagriSema to established medications such as semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda, Victoza). Its dual mechanism of action may offer a distinct therapeutic profile for patients.
CagriSema Alternatives: How It Compares to Other GLP-1 and Amylin Agonists
Hipa.ai Research · Source: ClinicalTrials.gov / AACT · Last updated: AI-augmented data · 6/7 curated
Source: ClinicalTrials.gov via AACT · Hipa.ai, 2026-05-07Download chart as PNG
The competitive landscape includes approved treatments such as Liraglutide (Saxenda, Victoza), approved in 2010, and Semaglutide (Wegovy), approved in 2017. While CagriSema is not yet approved, other pipeline drugs like Retatrutide, Orforglipron, and Survodutide are roughly 1-2 years behind in Phase 3 development.
Quick comparison table
| Drug | Class | Approved indications | Dosing | Year approved | Lead pivotal endpoint | Annual cost (rough) |
|---|---|---|---|---|---|---|
| CagriSema | Cagrilintide + Semaglutide combination | — | Investigational | Pipeline | — | — |
| Liraglutide (Saxenda, Victoza) | GLP-1 receptor agonist | type 2 diabetes, obesity, cardiovascular risk reduction | 3.0 mg once daily | 2014 | -7.46% @ 56 weeks | $16k |
| Semaglutide (Wegovy) | GLP-1 receptor agonist | chronic weight management, type-2 diabetes (Ozempic), cardiovascular risk reduction | 2.4 mg SC weekly (escalation from 0.25 mg over 16 weeks) | 2021 | -14.9% @ week 68 | $16k |
| Tirzepatide (Zepbound) | GIP/GLP-1 dual receptor agonist | chronic weight management, type-2 diabetes (Mounjaro), obstructive sleep apnea | 5–15 mg SC weekly (titration) | 2023 | -22.5% @ week 72 | $14k |
| Retatrutide | GLP-1/GIP/glucagon triple agonist | — | Investigational | Pipeline | — | — |
| Orforglipron | Oral non-peptide GLP-1 receptor agonist | — | Investigational; oral once-daily | Pipeline | — | — |
| Survodutide | GLP-1/glucagon dual agonist | — | Investigational | Pipeline | — | — |
Cost estimates are list-price approximations and do not reflect rebates, formulary tier, or out-of-pocket costs after benefits. The class-typical lead-pivotal endpoint here is Weight % change; cells render each drug's actual pivotal endpoint, which may differ. The "Year approved" column shows the FDA approval year for obesity specifically — drugs approved for other indications first appear with their this-indication date, or as Pipeline if not yet approved for this indication. Cross-trial comparisons can mislead — head-to-head Phase-3 data (when present) is below.
CagriSema vs Semaglutide (Wegovy)
The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT05669755) enrolling 7,101 participants, primary completion 2027-09.
Primary-endpoint values for NCT05669755 are not yet posted in the AACT results database.
Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.
CagriSema vs Tirzepatide (Zepbound)
The pivotal head-to-head evidence comes from a head-to-head Phase-3 trial (NCT06221969) enrolling 1,024 participants, primary completion 2026-03.
Primary-endpoint values for NCT06221969 are not yet posted in the AACT results database.
Source: ClinicalTrials.gov via AACT — pulled directly from the trial's posted results. View the full trial record.
CagriSema vs Liraglutide (Saxenda, Victoza)
No head-to-head Phase-3 trial directly compares CagriSema with Liraglutide.
Cross-trial caveat: the two drugs were tested in different patient populations at different time points. Cross-trial comparisons of response rates can mislead — the only rigorous comparison is a head-to-head randomized trial.
Pipeline alternatives
Several investigational agents are currently in active Phase 3 development. These include Retatrutide from Eli Lilly and Company, with its lead Phase 3 trial identified as NCT05931367. Another compound from Eli Lilly and Company is Orforglipron, which is also undergoing Phase 3 evaluation, with its lead trial at NCT05931380. Additionally, Survodutide, developed by Boehringer Ingelheim, is in Phase 3, with a lead trial listed as NCT06214741.
These investigational drugs represent a different mechanism of action compared to IL-17 inhibitors or agents like CagriSema, focusing instead on metabolic pathways. Their development timelines place them in active Phase 3, with specific progress varying across programs.
Choosing between CagriSema and its alternatives
For patients seeking a novel approach to weight management, the combination of cagrilintide and semaglutide, known as CagriSema, offers a dual mechanism of action. This therapy combines a GLP-1 receptor agonist with an amylin analog, aiming to leverage distinct physiological pathways for potentially enhanced efficacy. This differs from single-agent GLP-1 receptor agonists like semaglutide, which demonstrated a weight change of -14.9% at week 68, or dual GIP/GLP-1 receptor agonists such as tirzepatide, which showed a weight change of -22.5% at week 72. The combination strategy of CagriSema may be considered for individuals who could benefit from this synergistic effect.
Conversely, established agents like semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda, Victoza) remain important options. Semaglutide and tirzepatide are administered once weekly, offering convenience, while liraglutide requires once-daily dosing and showed a weight change of -7.46% at 56 weeks. These agents have extensive clinical experience and may be preferred based on factors such as cost, specific patient comorbidities, or individual response to a single-mechanism or dual GIP/GLP-1 approach. Ultimately, the choice of therapy should be a shared decision between the patient and their clinician, considering all relevant factors.
This information is not medical advice. Clinical decisions regarding specific treatments should always be made by a qualified healthcare provider in consultation with the patient.
Sources and methodology
Trial data was pulled from the ClinicalTrials.gov registry via the AACT relational mirror maintained by the Clinical Trials Transformation Initiative. AACT data freshness: .
Head-to-head trials cited on this page:
- NCT05669755: CagriSema vs Semaglutide · REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood Vesse…
- NCT06221969: CagriSema vs Tirzepatide · A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Typ…
Cross-trial comparison limitations:drugs without a direct head-to-head trial are compared using each drug's own pivotal trial. These trials enrolled different patient populations at different time points and used different statistical analysis sets. Cross-trial response-rate differences should not be interpreted as proof that one drug is more effective than another.
Related drug pages on Hipa.ai
Not medical advice. This page summarizes publicly-reported clinical trial data for informational purposes. Treatment decisions belong with a qualified prescribing clinician who knows your medical history. Drug approvals, dosing, and safety profiles change over time — always confirm with the current FDA prescribing information.
cagrisemacagrisema alternativesalternativescomparisonobesitycagrisema-amylin-glp1-obesitycagrisema vs semaglutidecagrisema vs tirzepatidecagrisema vs liraglutidecagrisema vs retatrutidecagrisema vs orforglipron